Search Results - "Compter I"

PO-1676: Blood biomarkers for cognitive damage after PCI; an exploratory analysis of the HA-PCI phase 3 trial.

Authors: Compter, I. Oldoni, E. Houben, R. et al.

Source: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS921-S922. 2p.

Subjects: Biomarkers, Posters, Physics

High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial).

Authors: Zegers, C. M. L. Swinnen, A. Roumen, C. et al.

Source: Trials. 5/21/2024, Vol. 25 Issue 1, p1-11. 11p.

425P - CHLOROBRAIN phase IB trial: The addition of chloroquine, an autophagy inhibitor, to concurrent radiation and temozolomide for newly diagnosed glioblastoma.

Authors: Compter, I. Eekers, D. Hoeben, A. et al.

Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv154-v154. 1p.

PO-0894: Comparing the spatial integrity of 7 T and 3 T MR images for image-guided radiotherapy of brain tumors.

Authors: Peerlings, J. Compter, I. Janssen, F.M. et al.

Source: Radiotherapy & Oncology. May2017 Supplement 1, Vol. 123, pS492-S493. 1p.

EP-1845: Integration of 7T MRI into image-guided radiotherapy of glioblastoma: a feasibility study.

Authors: Compter, I. Peerlings, J. Eekers, D.B.P. et al.

Source: Radiotherapy & Oncology. Apr2016 Supplement 1, Vol. 119, pS867-S868. 1p.

Subjects: Glioblastoma multiforme treatment, Glioblastoma multiforme, Magnetic resonance imaging of the brain, Imaging of cancer, Cancer radiotherapy, Feasibility studies, Diagnosis

PO-0657: Does Radiomics have prognostic value in glioblastoma?

Authors: Compter, I. Leijenaar, R.T.H. Eekers, D.B.P. et al.

Source: Radiotherapy & Oncology. Apr2016 Supplement 1, Vol. 119, pS306-S307. 1p.

Subjects: Glioblastoma multiforme, Radiation doses, Radiotherapy, Cancer research, Oncology, Prognosis

PD-0208 REIRRADIATION WITH/WITHOUT TEMOZOLOMIDE RESULTS IN A MEDIAN SURVIVAL OF 11 MONTHS IN PATIENTS WITH RECURRENT GLIOMA

Authors: Compter, I. Houben, R.M.A. Jager, J.J. et al.

Source: Radiotherapy & Oncology. May2012 Supplement, Vol. 103 Issue s1, pS80-S80. 1p.

8722 POSTER Stereotactic Radiotherapy of Meningiomas – a Long-term Follow-up Study With Regard to Local Control, Survival and Morbidity

Authors: Compter, I. Zaugg, K. de Kunder, S.L. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS581-S581. 1p.

PD-0540: A pooling method for feature selection of quantitative imaging analysis: survival analysis in glioma.

Authors: Shi, Z. Zhang, C. Compter, I. et al.

Source: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS299-S300. 2p.

Subjects: Feature selection, Survival analysis (Biometry), Image analysis, Quantitative research, Gliomas

Myasthenia gravis after glioblastoma resection: paraneoplastic syndrome or coincidence? A unique case report and review of the literature.

Authors: Slegers, R. J. Bouwens van der Vlis, T. A. M. Ackermans, L. et al.

Source: Acta Neurochirurgica. Feb2022, Vol. 164 Issue 2, p423-427. 5p.

PO-1868 Quantifying movement of optical structures during radiotherapy treatment.

Authors: Hofstede, D. Vaassen, F. Zegers, C.M. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS1610-S1612. 3p.

PD-0401 The effect of dose to the brain on early self-reported neurocognition; does low dose matter?

Authors: Vaassen, F. Hofstede, D. Zegers, C.M. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS301-S303. 3p.

MO-0556 Reduction of the CTV margin in glioblastoma leads to dosimetric benefit without compromising outcome.

Authors: Di Perri, D. Hartgerink, D. Terhaag, K. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS435-S437. 3p.

MO-0550 Correlations between cerebral cortical thickness, radiation dose and verbal memory performance.

Authors: Budé, I. de Jong, J. Lackner, N. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS430-S432. 3p.

Pattern of failure in IDH mutated, low grade glioma after radiotherapy – Implications for margin reduction.

Authors: Jaspers, J.P.M. Méndez Romero, A. Wiggenraad, R. et al.

Source: Radiotherapy & Oncology. Mar2021, Vol. 156, p43-48. 6p.

PO-1959 Dosimetric benefits of proton therapy over (non)-coplanar photon radiotherapy in pituitary adenoma.

Authors: Nogarede, M. Swinnen, A. Decabooter, E. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS1721-S1722. 2p.

MO-0478 Clinical benefit of proton treatment planning based on dual energy CT for neuro-oncological patients.

Authors: Taasti, V. Decabooter, E. Eekers, D. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS385-S386. 2p.

SP-0013 Weekly contouring rounds and education movies to improve organ at risk delineation in neuro-oncology.

Authors: Di Perri, D. Hofstede, D. Postma, A. et al.

Source: Radiotherapy & Oncology. 2022 Supplement 1, Vol. 170, pS3-S4. 2p.

Toward Shared Decision: Validated Clinical Nomogram for Personalized Long-Term Survival Prediction After Radiosurgery for Brain Metastases.

Authors: Zindler, J.D. Jochems, A. Beumer, R. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Oct2016 Supplement, Vol. 96, pS181-S181. 1p.

OC-0059: Validated clinical model for survival prediction after stereotactic radiotherapy for brain metastases.

Authors: Zindler, J. Beumer, R.J. Troost, E.G.C. et al.

Source: Radiotherapy & Oncology. 2014 Supplement, Vol. 115, pS29-S29. 1p.